4-Chlor-2,6-dimethylbenzamid | 85374-88-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-Chlor-2,6-dimethylbenzamid
• 英文别名: 4-Chloro-2,6-dimethylbenzamide
• CAS: 85374-88-5
• 化学式: C₉H₁₀ClNO
• 分子量: 183.637
• InChiKey: WSWCPPKGOMDSCA-UHFFFAOYSA-N

物化性质

• 熔点：
  185 °C
• 沸点：
  250.3±40.0 °C(Predicted)
• 密度：
  1.203±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  43.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  4-Chlor-2,6-dimethylbenzamid 在 sodium nitrite 作用下， 以 硫酸 为溶剂， 生成 4-氯-2,6-二甲基苯甲酸
  参考文献：
  名称：

  Effenberger, Franz; Epple, Gerhard; Eberhard, Joachim K., Chemische Berichte, 1983, vol. 116, # 3, p. 1183 - 1194

  摘要：

  DOI：
• 作为产物：
  描述：

  4-chloro-2,6-dimethylbenzonitrile 在 水 作用下， 生成 4-Chlor-2,6-dimethylbenzamid
  参考文献：
  名称：

  Effenberger, Franz; Epple, Gerhard; Eberhard, Joachim K., Chemische Berichte, 1983, vol. 116, # 3, p. 1183 - 1194

  摘要：

  DOI：

文献信息

• Pyrrole Derivatives As Pharmaceutical Agents
  申请人：Canne Bannen Lynne

  公开号：US20080234270A1

  公开（公告）日：2008-09-25

  Compounds, compositions and methods for modulating the activity of receptors are provided. In particular compounds and compositions are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder directly or indirectly related to the activity of the receptors.

  提供了用于调节受体活性的化合物、组合物和方法。特别提供了用于调节受体活性的化合物和组合物，以及用于治疗、预防或改善与受体活性直接或间接相关的一种或多种疾病或紊乱的症状的方法。
• N-phenyl benzimidazolecarboxamide and N-phenyl indolecarboxamide derivatives
  申请人：Neurogen Corporation

  公开号：US20020025977A1

  公开（公告）日：2002-02-28

  Disclosed are compounds of the formula: 1 or the pharmaceutically acceptable non-toxic salts thereof wherein; A is N or CH; R 1 and R 2 represents hydrogen or lower alkyl; G, R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are variables defined herein. These compounds are modulators of CRF receptors and are therefore useful for treating affective disorders, anxiety, depression, eating disorders, and stress disorders in humans and other animals. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also provided. Compounds of the invention are also useful as probes for the localization of CRF receptors and as standards in assays for CRF receptor binding. Methods of using the compounds in receptor localization studies are given.

  本发明涉及以下公式的化合物：1或其药学上可接受的非毒性盐，其中：A为N或CH; R1和R2代表氢或低碳基; G，R3，R4，R5，R6，R7和R8是在此定义的变量。这些化合物是CRF受体调节剂，因此可用于治疗人类和其他动物的情感障碍、焦虑、抑郁、进食障碍和压力障碍。本发明还提供了治疗此类障碍的方法以及包装的药物组成物。本发明的化合物也可用作CRF受体定位探针和CRF受体结合测定的标准。给出了在受体定位研究中使用该化合物的方法。
• Urea Derivative
  申请人：Kurata Hitoshi

  公开号：US20070249620A1

  公开（公告）日：2007-10-25

  The present invention relates to a urea derivative or a pharmacologically acceptable salt thereof having an excellent DGAT inhibitory effect. A urea derivative having the formula: [wherein R 1 is a C 6 -C 10 aryl group which may be independently mono- to pentasubstituted by a group selected from Substituent Group a or others; R is a C 6 -C 10 aryl group which may be independently mono- to pentasubstituted by a group selected from Substituent Group a or others; E is a group having the formula (II) or the formula (III) (wherein R 3 is a hydrogen atom or others; R 4 and R 5 , which are the same or different, are a hydrogen atom or others; X and U, which are the same or different, are a group represented by the formula CH or others; m and n, which are the same or different, are I or another number) or others; and A is a group represented by the formula —NH—C(═O)— or others], or a pharmacologically acceptable salt thereof.

  本发明涉及一种具有出色DGAT抑制作用的脲衍生物或其药理学上可接受的盐。其中，该脲衍生物具有以下公式：[式中，R1是C6-C10芳基，可以独立地被来自置换基团a或其他的基团单独到五重取代；R是C6-C10芳基，可以独立地被来自置换基团a或其他的基团单独到五重取代；E是具有公式（II）或公式（III）的基团（其中，R3是氢原子或其他；R4和R5相同或不同，是氢原子或其他；X和U相同或不同，是由公式CH或其他表示的基团；m和n相同或不同，是I或其他数字）或其他；A是由公式—NH—C(═O)—或其他表示的基团]，或其药理学上可接受的盐。
• UREA DERIVATIVE
  申请人：Sankyo Company, Limited

  公开号：EP1764360A1

  公开（公告）日：2007-03-21

  The present invention relates to a urea derivative or a pharmacologically acceptable salt thereof having an excellent DGAT inhibitory effect. A urea derivative having the formula: [wherein R1 is a C6-C10 aryl group which may be independently mono- to pentasubstituted by a group selected from Substituent Group a or others; R2 is a C6-C10 aryl group which may be independently mono- to pentasubstituted by a group selected from Substituent Group a or others; E is a group having the formula (II) or the formula (III) (wherein R3 is a hydrogen atom or others; R4 and R5, which are the same or different, are a hydrogen atom or others; X and U, which are the same or different, are a group represented by the formula CH or others; m and n, which are the same or different, are 1 or another number) or others; and A is a group represented by the formula -NH-C(=O)- or others], or a pharmacologically acceptable salt thereof.

  本发明涉及一种脲衍生物或其药理上可接受的盐，具有极佳的 DGAT 抑制作用。一种脲衍生物具有以下式子： [其中 R1 是 C6-C10 芳基，可独立地被选自取代基 a 或其它的基团一至五取代；R2 是 C6-C10 芳基，可独立地被选自取代基 a 或其它的基团一至五取代；E 是具有式(II)或式(III)的基团（其中 R3 是氢原子或其它；R4和R5相同或不同，为氢原子或其它；X和U相同或不同，为式CH代表的基团或其它；m和n相同或不同，为1或其它数字）或其它；以及A为式-NH-C(=O)-代表的基团或其它]，或其药理学上可接受的盐。
• EFFENBERGER, F.;EPPLE, G.;EBERHARD, J. K.;BUEHLER, U.;SOHN, E., CHEM. BER., 1983, 116, N 3, 1183-1194
  作者：EFFENBERGER, F.、EPPLE, G.、EBERHARD, J. K.、BUEHLER, U.、SOHN, E.

  DOI：——

  日期：——